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Introduction
Pneumococcal diseases (PDs) are a major cause of mor-
bidity and mortality worldwide. Pneumococcal conjugate
7-valent vaccine (PCV7) was introduced in national
immunization programs (NIPs) in 2006 in many European
countries; higher valency PCVs became available in 2009-
2012.
Objectives
To describe the incidence and evolution of serotype dis-
tribution of IPD in all ages.
Methods
Medline, Embase, public health websites and conference
abstracts were searched from January 2010-July 2012 for
data on incidence and S. pneumoniae serotype distribu-
tion in all PDs and nasopharyngeal carriage in all ages
in Western Europe. Here we present only the data for
serotype distribution in IPDs between 2005-2011.
Results
We identified 1431 sources; of the 124 included, 70
reported serotype data in children and adults with IPD
from 15 countries. Before PCV introduction, PCV7 and
PCV13 serotypes represented 53-77% and 91% of those
found in children and 14-46% and 75% in adults, respec-
tively. After PCV7 introduction this changed to 1-29%
and 81-94% in children and 13-31% and 68-70% in
adults. Before PCV introduction the most prevalent ser-
otypes (≥5%) were 14, 19A, 1, 23F, 19F, 6B, 18C, 7F, 9V
in children and 14, 3, 7F, 4, 5, 1, 9V, 19A, 23F, 6B in
adults. After PCV7 introduction the most prevalent
serotypes were 19A, 7F, 14, 3, 1, 6A, 18C, 5 in children
and 7F, 19A, 1, 3, 15, 14, 4, in adults. The distributions
differed across the countries.
Conclusion
After PCV7 introduction, in both children and adults,
the prevalence of PCV7 serotypes was reduced, while
serotypes 1, 19A, 7F, 3 and 6A became relatively more
prevalent. Newly available PCVs including more sero-
types will be helpful in effective control of PDs caused
by these serotypes. Continuous surveillance is necessary
for better understanding of evolution of PDs in the PCV
vaccination era.
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